Alkermes

Improving cancer immunotherapy by recovering a warning system Cancer cells, most of the time, develop tactics to elude the immune system. A research team that is led by scientists at Memorial Sloan Kettering Cancer Center has recognized one such mechanism, and it believes aiming it with drugs could potentially e...

U.S., AstraZeneca strikes an antibody treatment USD 486 million deal The U.S. government awarded the pharma giant AstraZeneca a sum of USD 486 million for the development of up to 100,000 corona vaccine doses. The deal, under Operation Warp Speed, will people the manufacturing of antibody doses and facilitate th...

Novo Nordisk has announced to enter into a collaboration with Dicerna’s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to advance the treatment landscape of the diseases such as non-alcoholic steatohepatitis (NASH), Type 2 diabetes and obesity. Nordisk will be inv...

FDA discards depression drug ALKS 5461 of Alkermes The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine and samidorphan. Alkermes designed the combination to act on the mu- and kappa-opioid receptors that eventually showed im...

Alkermes Gets FDA approval for Aristada Initio (aripiprazole lauroxil) as Part of  Schizophrenia Treatment Combination  Alkermes has announced that the U.S. FDA approved ARISTADA INITIO (aripiprazole lauroxil) for the initiation of ARISTADA (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic f...